A phase 2 study of abemaciclib in patients with brain metastases secondary to non-small cell lung cancer or melanoma
{{output}}
Background: Abemaciclib is a selective cyclin-dependent kinase 4 and 6 inhibitor that penetrates the blood-brain barrier, resulting in comparable concentrations in tissue and plasma. The primary objective of this nonrandomized Si... ...
